A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07258511
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-79635322 — DRUG
    JNJ-79635322 will be administered as SC injection.
  • Teclistamab — DRUG
    Teclistamab will be administered as SC injection.

Study Details

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Key Dates

Start date
Feb 4, 2026
Status verified
Jun 2026
Primary completion
Dec 12, 2028
Completion
Sep 30, 2031

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: JNJ-79635322
    Participants will receive subcutaneous (SC) dose of JNJ-79635322 until progressive disease (PD) or intolerable toxicity.
  • Active Comparator: Anti BCMAxCD3 Bispecific Antibody
    Participants will receive teclistamab (an Anti BCMAxCD3 bispecific anitbody) as a SC injection until PD or intolerable toxicity.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to 5 years and 4 months ]

Central Contacts

Locations (23)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
Colorado Blood Cancer InstituteDenverColorado80218-
University of Connecticut Health CenterFarmingtonConnecticut06030-
Yale Cancer CenterNew HavenConnecticut06510-
Florida Cancer Specialists & Research InstituteFort MyersFlorida33901-
Moffit Cancer centerTampaFlorida33612-
Emory UniversityAtlantaGeorgia30322-
University of Iowa Hospital and ClinicsIowa CityIowa52242-
Mission Cancer BloodWaukeeIowa50263-
Norton Cancer InstituteLouisvilleKentucky40207-
Mount Sinai BrooklynBrooklynNew York11234-
NYU WinthropMineolaNew York11501-
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-
Laura and Isaac Perlmutter Cancer Center NYU ACCNew YorkNew York10016-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Mount Sinai ChelseaNew YorkNew York10011-
Durham VAMCDurhamNorth Carolina27705-
Oregon Health And Science UniversityPortlandOregon97239-
Thomas Jefferson University HospitalPhiladelphiaPennsylvania19107-
SCRI Oncology PartnersNashvilleTennessee37203-
St. David's South Austin Medical CenterAustinTexas78704-
Baylor University Medical CenterDallasTexas75246-
Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in Los Angeles, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
USC Norris Comprehensive Cancer Center· Los Angeles, CAColorado Blood Cancer Institute· Denver, COUniversity of Connecticut Health Center· Farmington, CTYale Cancer Center· New Haven, CTFlorida Cancer Specialists & Research Institute· Fort Myers, FLMoffit Cancer center· Tampa, FL

Related Studies